Principal Scientific Adviser to GoI reviews progress to transform India regulatory ecosystem for medical products

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-08-22 06:00 GMT   |   Update On 2024-08-22 06:00 GMT

New Delhi: Prof. Ajay Kumar Sood, Principal Scientific Adviser (PSA) to the Government of India took a meeting to review the progress made towards transformation of India's regulatory system. This matter was discussed in the 24th PM-Science Technology Innovation Advisory Council (PM-STIAC) meeting, chaired by the PSA, and held on the 6th of February 2024 on ‘Transforming the regulatory ecosystem of the medical products in India’.

The PM-STIAC meeting had recommended comprehensive overhauling of the regulatory processes and working towards building a system that ensures transparency, accountability and at the same time promotes innovation and introduction of safe and affordable medical products for India and the world.

Dr. Rajeev Raghuvanshi, Drug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) updated the progress in priority areas identified as part of the PM-STIAC meeting, such as streamlining of the Subject Expert Committee (SEC) review process and internal process improvement with the help of an independent external agency. He also elaborated on the development of an end-to-end digital architecture for the transformation of India’s regulatory ecosystem, consolidation of Review Committee on Genetic Manipulation (RCGM) activities to a single window system thereby reducing the timeline of approvals, developing the scientific capacity of CDSCO, increased digitization, and the recent notification of countries under Rule 101 to simplify access to medical products, among others.

Read also: Daiichi Sankyo, AstraZeneca Enhertu gets USFDA breakthrough therapy designation for certain patients with HER2 low or HER2 ultralow metastatic breast cancer

PSA Prof. Sood appreciated the efforts of CDSCO and emphasized that a robust and enabling regulatory ecosystem will help to build trust in domestic and international markets, boost manufacturing and exports. He said that these efforts will further augment the competitive advantage that India has in the manufacturing of medical products and spur innovations in the entire sector.

Read also: Shri Arunish Chawla assigned to additional role of Chairman, National Pharmaceuticals Pricing Authority

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News